Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PCWMQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CLL1-ADC
|
|||||
| Synonyms |
CLT 030 ADC; CSC-030; CSC-030-ADC; CLT-030-ADC
Click to Show/Hide
|
|||||
| Organization |
Cellerant Therapeutics, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Fully humanized Anti-CLL1 mAb
|
Antibody Info | ||||
| Antigen Name |
C-type lectin domain family 12 member A (CLEC12A)
|
Antigen Info | ||||
| Payload Name |
D211
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-PEG8-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Maleimide functional group to conjugate the linker-payload to reactive thiol groups on the antibody consisting of 2 engineered cysteine residues.
|
|||||
| Combination Type |
D212
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.